Stock Events

Stock Events

Fate Therapeutics 

€1.82
92
+€0.55+43.2% Tuesday 14:14

Statistics

Day High
1.82
Day Low
1.82
52W High
1.82
52W Low
0.83
Volume
157
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q4 2025
Next
-0.24
-0.24
-0.23
-0.23
Expected EPS
-0.23894920000000003
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow F6T.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the cell therapy space targeting similar diseases.
Novartis
NVS
Mkt Cap279.67B
Novartis offers CAR-T cell therapies, directly competing in the oncology segment with cell-based therapies.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR-T therapy space, similar to Fate's focus.
Allogene Therapeutics
ALLO
Mkt Cap739.55M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, directly competing with Fate's off-the-shelf cell therapy approach.
Sangamo Therapeutics
SGMO
Mkt Cap55.93M
Sangamo Therapeutics is involved in genome editing and gene therapy, competing in the broader cell and gene therapy market.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical develops gene therapies for genetic diseases, indirectly competing in the cell and gene therapy sector.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has investments in gene therapy and CAR-T cell therapy, making it a competitor in the cell therapy market.
First Trust Indxx NextG
NXTG
Mkt Cap0
NextCure focuses on novel immunomedicines, competing in the immune-oncology market with a focus on novel cell therapies.

About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Bahram Valamehr M.B.A., Ph.D.
Employees
181
Country
United States
ISIN
US31189P1021

Listings

MU
DE
F6T.MU
STU
DE
F6T.STU
XNAS
US
FATE
F
DE
F6T.F

0 Comments

Share your thoughts

FAQ

What is Fate Therapeutics stock price today?▼
The current price of F6T.MU is €1.82 EUR — it has increased by +43.2% in the past 24 hours. Watch Fate Therapeutics stock price performance more closely on the chart.
What is Fate Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Fate Therapeutics stocks are traded under the ticker F6T.MU.
Is Fate Therapeutics stock price growing?▼
F6T.MU stock has risen by +55.61% compared to the previous week, the month change is a +75.88% rise, over the last year Fate Therapeutics has showed a +71% increase.
How many employees does Fate Therapeutics have?▼
As of May 06, 2026, the company has 181 employees.
In which sector is Fate Therapeutics located?▼
Fate Therapeutics operates in the Health & Wellness sector.
When did Fate Therapeutics complete a stock split?▼
Fate Therapeutics has not had any recent stock splits.
Where is Fate Therapeutics headquartered?▼
Fate Therapeutics is headquartered in San Diego, United States.